Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2026)
Barinthus Biotherapeutics' (BRNS) quarterly Operating Expenses came in at $6.1 million in Q1 2026, down 70.75% YoY from $20.9 million in Q1 2025, and down 47.11% on a QoQ basis from $11.6 million in Q4 2025.
Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2026) Analysis & Trends
Barinthus Biotherapeutics (BRNS) has 7 years of Operating Expenses data on file, last reported at $6.1 million in Q1 2026.
- Quarterly Operating Expenses fell 70.75% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $56.3 million (down 36.02% YoY) and the FY2025 annual result came in at $71.1 million, down 15.52% from the prior year.
- Operating Expenses eased to $6.1 million in Q1 2026, from $11.6 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $31.6 million in Q4 2022 to a low of -$1.1 million in Q3 2022.
- A 5-year average of $17.3 million and a median of $18.9 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses tumbled 119.28% — and 2023, when it soared 1603.73%.
- Tracing BRNS's Operating Expenses over 5 years: stood at $31.6 million in 2022, then slumped by 36.65% to $20.0 million in 2023, then gained by 17.94% to $23.6 million in 2024, then sank by 50.91% to $11.6 million in 2025, then plunged by 47.11% to $6.1 million in 2026.
- The last three Operating Expenses figures came in at $6.1 million (Q1 2026), $11.6 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.06 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -784.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 427.03 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 541.02 Mn |
| 10 | Barinthus Biotherapeutics | 25.40 Mn | 25.40 Mn | - | 11.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.02 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | 11.57 Mn |
| Sep 30, 2025 | 15.22 Mn |
| Jun 30, 2025 | 23.34 Mn |
| Mar 31, 2025 | 20.93 Mn |
| Dec 31, 2024 | 23.57 Mn |
| Sep 30, 2024 | 24.56 Mn |
| Jun 30, 2024 | 18.86 Mn |
| Mar 31, 2024 | 17.12 Mn |
| Dec 31, 2023 | 19.99 Mn |
| Sep 30, 2023 | 16.11 Mn |
| Jun 30, 2023 | 26.67 Mn |
| Mar 31, 2023 | 21.95 Mn |
| Dec 31, 2022 | 31.55 Mn |
| Sep 30, 2022 | -1.07 Mn |
| Jun 30, 2022 | 3.83 Mn |
| Mar 31, 2022 | 14.36 Mn |
| Dec 31, 2021 | 16.67 Mn |
| Sep 30, 2021 | 5.56 Mn |